Investment Rating - The report assigns an "Accumulate" rating for the company for the first time [1] Core Insights - The company is a leader in the medical sodium hyaluronate dressing market and is actively expanding into class III medical devices [4] - The company has established a diverse product matrix focusing on functional skincare products and class II medical devices, leveraging core technologies of sodium hyaluronate and collagen [16][17] - The online direct sales ratio has been steadily increasing, with significant growth on platforms like Tmall and Douyin [28][33] - The company's stock ownership is highly concentrated, with the chairman holding 84.41% of shares, which enhances operational execution and team stability [34][38] Financial Forecast - The company's total revenue is projected to be 1,823.46 million yuan in 2025, with a year-on-year decline of 9.59%, followed by a recovery to 2,054.34 million yuan in 2026, and 2,259.77 million yuan in 2027 [7][9] - The net profit attributable to shareholders is expected to be 452.41 million yuan in 2025, down 31.57% year-on-year, followed by 502.92 million yuan in 2026 and 539.82 million yuan in 2027 [7][9] - The company's price-to-earnings (P/E) ratios for 2025-2027 are projected to be 27.6, 24.8, and 23.1 times, respectively [7][9] Industry Overview - The professional skincare industry in China has seen significant growth, with the market size for functional skincare products and medical dressings expected to reach 623.0 billion yuan and 253.8 billion yuan by 2026, respectively [52][56] - The market for professional skincare products has grown from 102.5 billion yuan in 2017 to 309.6 billion yuan in 2021, with a compound annual growth rate (CAGR) of 31.8% [52][56] - The competitive landscape in the medical dressing market is fragmented, with the company holding a 10.1% market share, making it the leading brand in the industry [60]

Investment Rating - The report assigns an "Accumulate" rating for the company for the first time [1] Core Viewpoints - The company is a leader in the medical sodium hyaluronate dressing market and is actively expanding its product line to include type III human-derived collagen products [4] - The company has a strong channel advantage, having expanded its medical dressing products from public hospitals to various medical institutions, beauty organizations, and retail pharmacies [9] - The online direct sales ratio has been steadily increasing, from 24.97% in 2020 to an expected 49.67% in 2024, indicating a shift towards e-commerce [9] Financial Forecast - Total revenue is projected to be 1,933.50 million yuan in 2023, with a growth rate of 9.29%, and is expected to reach 2,259.77 million yuan by 2027, with a growth rate of 10.00% [7] - Net profit attributable to the parent company is forecasted to be 749.34 million yuan in 2023, declining to 452.41 million yuan in 2025, before recovering to 539.82 million yuan by 2027 [7] - The company's price-to-earnings (P/E) ratios for 2025-2027 are projected to be 27.6, 24.8, and 23.1 times, respectively [9] Industry Overview - The professional skin care product market in China has grown from 180.5 billion yuan in 2017 to 317.1 billion yuan in 2021, with a compound annual growth rate (CAGR) of 15.1% [48] - The market for functional skin care products and medical dressings is expected to reach 623.0 billion yuan and 253.8 billion yuan, respectively, by 2026 [53] - The competitive landscape in the medical dressing market is fragmented, with the company holding a 10.1% market share, making it the leading brand in the industry [9][61]

Group 1: Channel Optimization and Sales Outlook - The company's offline channel optimization is progressing as expected, focusing on "strong regulation + strong optimization" to enhance market control and balance inventory levels to avoid excess stock risks [2] - The sales outlook for 2026 will be assessed after the release of periodic reports, with the company committed to maintaining strong offline sales efforts [3] Group 2: New Product Planning - The company has a well-prepared new product plan for 2026, covering various product forms including dressings, masks, lotions, creams, and serums, with actual launches to be confirmed later [3] Group 3: Non-Patch Product Revenue Trends - Since the establishment of the Shanghai R&D center, the company has increased its focus on non-patch products, leading to a rising revenue share from these products [3] Group 4: OTC Channel Development - The current coverage of the OTC channel is relatively low, indicating significant expansion potential; the company plans to increase personnel in this area to improve pharmacy coverage [3] Group 5: Sales Performance and Promotions - Sales during the 38 Festival are meeting expectations, with a focus on daily sales complemented by promotional activities to enhance overall performance [3] Group 6: Product Development Progress - Clinical trials for the recombinant type III humanized collagen freeze-dried fibers have been completed, with submission materials being prepared; other products are at various stages of clinical trials [3] Group 7: Shareholder and Acquisition Plans - The chairman has no current plans to reduce his shareholding, and while the company is monitoring potential acquisition targets, there are no suitable candidates at this time [3] Group 8: Dividend Considerations - The dividend proposal for the fiscal year 2025 has not yet been determined, and stakeholders are encouraged to stay updated [4]

Group 1: Sales and Market Strategy - The company's offline channel optimization is progressing as expected, focusing on "strong regulation + strong optimization" to enhance market control and balance inventory levels to avoid excess stock risks [2] - The sales outlook for 2026 will be assessed after the release of periodic reports, with the company committed to maintaining offline sales efforts [3] - The company has increased personnel in the OTC channel to improve pharmacy coverage, indicating significant growth potential in this area [3] Group 2: Product Development and Innovation - The company has a well-prepared product plan for 2026, including various new product forms such as dressings, masks, lotions, creams, and serums [3] - Since the establishment of the Shanghai R&D center, the revenue share of non-patch products has been increasing due to ongoing R&D efforts [3] - Progress on three types of medical devices includes completion of clinical trials for recombinant type III humanized collagen freeze-dried fibers and initiation of clinical trials for other products [3] Group 3: Financial and Corporate Governance - The chairman has no plans to reduce his shareholding in the company, ensuring stability in corporate governance [3] - The dividend plan for the fiscal year 2025 has not yet been determined, pending further developments [4] - The company is monitoring potential acquisition projects but currently has no suitable targets [3]

Product Structure - The company's products are mainly divided into two categories: medical devices and functional skincare products [2] - Non-patch products include various forms such as water, essence, lotion, spray, lyophilized, and single-use essence [2] Non-Patch Product Revenue - The revenue share of non-patch products is continuously increasing following the establishment of the Shanghai R&D center, which has accelerated the speed of new product launches [2] Medical Device Progress - The company is making significant progress with three types of medical devices, including recombinant type III humanized collagen protein lyophilized fibers and dressings, with clinical trials completed for the former [3] - The injectable recombinant type III humanized collagen protein gel is expected to start clinical trials this year [3] Pricing Stability - The pricing situation for the company's products is stable, with overall price differences across channels being controllable [3] - Price fluctuations among mainstream channels remain within a reasonable range, with promotional strategies employed to balance sales and pricing during peak periods [3] Aesthetic Medicine Strategy - The company is strategically entering the aesthetic medicine sector due to its pharmaceutical background, aligning medical device products with existing offerings [3] - The company is monitoring potential acquisition targets in the aesthetic medicine field and will adhere to regulatory disclosure obligations for any developments [3] Dividend Policy - The company has maintained a positive attitude towards returning profits to investors through cash dividends since its listing, although specific dividend amounts will depend on performance and financial planning [3] Equity Incentives - The company has plans for equity incentives as the management team evolves, with intentions to disclose specific details in future announcements [3]

Core Viewpoint - Fulejia, known as the "first stock of medical beauty masks," is facing significant challenges, with a reported revenue decline of 11.54% year-on-year for the first three quarters of 2025, totaling 1.297 billion yuan. The company aims to achieve at least 700 million yuan in revenue in the fourth quarter, which appears to be a considerable challenge [2]. Group 1: Business Performance and Challenges - Fulejia's revenue for the full year of 2024 was 2.017 billion yuan, indicating a need for substantial growth in Q4 2025 to meet targets [2]. - The company's medical device product revenue share has decreased from 55.54% in 2020 to 42.28% in 2024, and further down to 27.61% in the first half of 2025, highlighting a significant impact on its financial performance [9]. - The tightening of regulations regarding "medical beauty masks" has created a clearer distinction between medical devices and cosmetic products, further complicating Fulejia's market position [6][7]. Group 2: Product Development and Market Strategy - Fulejia has made progress in its Class III medical device projects, with a new product, "recombinant type III humanized collagen dressing," entering clinical stages, while other products are in various stages of development [2][4]. - The shift towards Class III medical devices is part of a broader trend among beauty brands, as many are moving away from Class II products due to market saturation and regulatory challenges [3][4]. - Fulejia's entry into the Class III market is seen as a strategy to strengthen its position in the medical beauty sector, although it is currently lagging behind competitors who have already secured Class III registrations [4]. Group 3: Transition to Cosmetics - Fulejia's cosmetics business has seen growth, with revenue surpassing that of medical devices for the first time in 2022, indicating a strategic pivot [11]. - However, the brand still faces challenges in changing consumer perceptions from a medical mask brand to a cosmetics brand, as many consumers associate Fulejia primarily with medical beauty masks [12]. - The company has encountered complaints regarding its cosmetic products, raising concerns about safety and efficacy, which could hinder its ability to attract new customers [12]. Group 4: Research and Development - Fulejia's R&D investment for the first three quarters of 2025 was 36.31 million yuan, with a R&D expense ratio of 2.8%, which, while improved, remains low compared to competitors [14]. - The company holds a total of 61 patents, but the majority are design patents, indicating a potential weakness in innovation compared to peers in the beauty industry [14]. - Balancing R&D investments between medical devices and cosmetics presents a challenge for Fulejia, as both sectors require significant resources to remain competitive [16].

Core Viewpoint - The company Fuhua (301371) is progressing in its R&D projects, with specific timelines and developments for its medical devices and injectable products outlined for 2025 [1] R&D Progress - The company has a Class III medical device, "Recombinant Type III Humanized Collagen Dressing," which has entered the clinical stage for 2025 [1] - For injectable products, the clinical trials for the "Recombinant Type III Humanized Collagen Lyophilized Fiber" project have been completed, and the company is preparing the clinical trial summary report [1] - The "Recombinant Type III Humanized Collagen Gel" project is still in the R&D phase, with plans to initiate clinical trials this year [1] - Further updates on other R&D projects will be available in the annual report scheduled for release in April [1]

Product Launch and Development - In November and December 2025, the company launched a total of 18 new products, with 9 in medical devices and 9 in cosmetics [1] - The company has a clinical-stage medical device, "Recombinant Type III Humanized Collagen Dressing," and is preparing for clinical trials for other collagen-based products [2] Financial Performance and Sales Strategy - The company is currently finalizing its financial results for 2025, with sales data impacted by adjustments in offline sales channels [2] - The transition from traditional distribution to value-driven sales models is expected to improve long-term health in offline business [2] Margin and Cost Management - The company is experiencing pressure on profit margins due to high online sales costs and adjustments in offline sales channels [4] - The fluctuation in gross margin is attributed to increased competition and changes in product mix, with plans for optimization in production, pricing, and supply chain management [2] Channel Optimization and Inventory Management - The company is optimizing its offline channels, focusing on better inventory management and strategic partnerships with service-oriented distributors [4] - Current adjustments in offline channels are expected to have manageable impacts on performance, laying the groundwork for future growth [4] Future Plans and Incentives - The company expresses a strong intention to implement an equity incentive plan as the management team evolves [4]

Core Viewpoint - The beauty and medical aesthetics industry is experiencing a stark contrast, with medical aesthetic companies facing significant pressure while domestic beauty brands are actively entering the medical aesthetics market [3][4][5] Medical Aesthetics Industry Performance - Among 22 medical aesthetics companies, 14 reported a year-on-year decline in revenue during the first half of the year, with "medical aesthetics trio" member Aimeike experiencing a decline exceeding 20% [4][5] - The medical aesthetics market has been growing rapidly, with a projected market size of nearly 3,700 billion by 2025, growing at an annual rate of 17.4% since 2020 [4] Competitive Landscape - The medical aesthetics industry is facing intensified competition, particularly in upstream raw materials and equipment, leading to declining revenues for companies like Aimeike and Haohai Biological [6][7] - The consumer market is becoming more rational, with 73% of mid-to-high-income consumers planning to reduce or maintain their medical aesthetics spending in 2024 compared to 2023 [7] Domestic Beauty Brands' Strategies - Over 20 domestic beauty companies are entering the medical aesthetics sector, with brands like Naturating and Youshiyan launching new products aimed at the medical aesthetics market [10][12] - Baijuerling has launched three medical aesthetics brands, focusing on injection regeneration, post-operative care, and medical equipment, indicating a comprehensive approach to the medical aesthetics industry [16][20] Market Challenges and Opportunities - The market for medical aesthetics is becoming increasingly competitive, with established brands like 可复美 and 薇诺娜 already dominating the "medical device" segment, making differentiation a key challenge for new entrants [22][25] - Despite the challenges, the structural adjustment in the medical aesthetics industry presents opportunities for collaboration and innovation, as companies explore new product offerings and partnerships [25][27]

Macro Economic Group - In May, US retail sales decreased by 0.9%, the largest drop since March 2023, exceeding expectations of a 0.6% decline [3] - Excluding automobiles, retail sales fell by 0.3%, while core retail sales, excluding gas stations, decreased by 0.1% [3] - The industrial production index for May showed a decrease of 0.2%, with manufacturing output slightly increasing by 0.1% [3] - US stock markets experienced declines, with the Dow down 0.7%, Nasdaq down 0.91%, and S&P 500 down 0.84% [3] - Oil prices rose by 5.4%, while gold and silver prices saw minor increases [3] Industry Comprehensive Group - Chip Qu Microelectronics signed contracts worth RMB 146 million for PCB production equipment, indicating optimism in the domestic PCB industry [5] - Major AI facility investors like Microsoft, Google, and Amazon are expected to increase capital expenditures by over $300 billion in 2025, a year-on-year growth of over 30% [5] - Taiwan's major PCB companies reported a 15% year-on-year revenue growth from January to May 2025, reflecting high industry demand [5] - BOE announced a plan to acquire a 30% stake in Xianyang Rainbow Optoelectronics for RMB 4.849 billion, which will enhance global TFT panel supply concentration [6] - The demand for TVs is expected to rise due to appliance consumption subsidies, positively impacting TFT panel profitability [6] Advanced Manufacturing Group - The recruitment for humanoid robots surged by 409%, with technical positions making up 62% of the total [8] - The robot industry is in a critical phase of technology development, with significant demand for talent in R&D and system debugging [8] - Investment strategies should focus on humanoid robot algorithms and automation, with long-term attention on full-stack technology and scenario positioning [8] - Tianqi Lithium and CATL established a lithium mining subsidiary, emphasizing resource control over procurement [9] - The establishment of the subsidiary reflects a strategic shift towards resource control in the lithium battery industry [9] Consumer Group - With summer approaching, searches for "graduation trips" have surged, particularly among young travelers [11] - Intercontinental Hotels Group has launched student-exclusive discounts and packages to cater to the rising demand from young tourists [11] - Fulejia announced the upcoming clinical trials for its collagen dressing, indicating growth potential in the medical aesthetics market [12]